DAY ONE 3 APRIL

DC Plenary Day April 3

MORNING PLENARIES

Dr Justin R Ortiz
08:40

Immunization across the lifespan – What will it take? A WHO perspective

  • Building routine influenza immunization programs in low-resource settings
  • Vaccinations in adulthood: An important role in public health and in reducing morbidity and mortality rates
  • Why are adults often behind in many vaccinations?
Dr Carl Alving
09:05

Adjuvant technology and its impact on vaccine development

  • Analysis of the importance and role of innate immunity
  • Formulation of novel adjuvant combinations
Dr Derek O'Hagan
09:30

Designing and building the next generation of vaccine adjuvants

  • Discovery of adjuvants, their optimal delivery and how they advance into clinical evaluation and assessment of their performance
  • Creating robust and scalable formulations
  • Negotiating a path to potential approval
Dr Mathuram Santosham
09:55

What it takes to get a vaccine from research to near elimination of H influenza type b (Hib) diseases globally: Saving 7 million lives by 2020

  • How the pivotal PRP-OMP conjugate vaccine efficacy trial was designed and conducted, leading to the licensure of the vaccine (Pedvax Hib)
  • Challenges and triumphs – lessons learned that can be applied to today’s vaccine research and trials for global access
10:20

Networking coffee break

11:20

INTERACTIVE ROUNDTABLES

Choose two roundtable sessions back-to-back and explore a range of topical issues that can be discussed with other thought leaders at a more interactive basis – 40 min per roundtable

Best practices for a Successful CRO/Pharma partnership for Vaccine Clinical Studies

Title TBC

Clinical Development & trials: Conducting clinical trials in low resource settings

Developing more effective vaccines for emerging/re-emerging pandemic threats

Senior representative, ClinicalRM TBC

Discovering pre-clinical genomic biomarkers of safety and efficacy in vaccine research, design and development

DNA, live vectors, adjuvanted vaccines. 30 years later, are they inter changeable or is there a specific use for each?

How can we actually apply big data and AI into smarter vaccine design?

How to measure and develop dual use vaccines?

Managing your cold chain – Lessons learned from the Ebola clinical trials

Non-clinical safety considerations when working with live virus and LNP based vaccines

Dr Lisa Plitnick, Senior Principal Scientist, Vaccines Therapeutic Area Lead, Safety Assessment and Laboratory Animal Resources, Merck Research Laboratories

Unexpected drivers of performance; doses per vaccine vial

12:40

Networking Lunch & Poster Session

AFTERNOON PLENARIES

Dr Vasee Moorthy
3:10

Enabling guidance from the World Health Organization

-          WHO’s target product profiles for outbreak vaccine development

-          Data and sample sharing in emergencies and during the inter-emergency period

3:40

Networking coffee break

Panel discussion
4:10

Executive cancer panel: How will recent breakthroughs in immuno-oncology determine cancer vaccine and combinational treatments?

  • The significance of check point inhibitors, oncolytic viruses neoantigens, CAR T-cells and ACT on cancer immunotherapy progress
  • Supporting evidence from combinational studies
  • The role of cancer vaccines in the future of combinational approaches
Dr Bruce Gellin
4:55

The role of vaccines to combat antibiotic-resistant bacteria

  • Insights and recommendations from the national vaccine advisory committee and Chatham house
  • Use of vaccines to prevent the infections that could or have developed AMR to antibiotics, in adjunction to antibiotic stewardship
Dr Gary Nabel
5:20

Trispecific abs and novel platforms to prevent HIV and other viral infections

Dr Gregory A. Poland
5:40

Chair’s closing remarks and close of congress day 1

5:50

Pre-Awards Networking Drinks Reception

6:50

Gala Dinner & 11th Annual ViE Awards Ceremony

last published: 14/Dec/17 14:05 GMT